Self-Delivering PTEN siRNA for Spinal Cord Injury
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for spinal cord injuries (SCI) face challenges in promoting axon regeneration due to limitations in growth factors, inhibitory proteins in the CNS environment, and the lack of effective clinical translation of experimental treatments, with existing delivery methods being inefficient and causing side effects.
Innovation Solution
Development of self-deliverable siRNAs (sdRNAs) targeting PTEN mRNA, which are modified to be cell-permeable and stable, allowing for local administration and effective inhibition of PTEN expression in mammalian cells, promoting axon regeneration and astrocyte migration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional delivery methods are used to administer growth factors or drugs to promote axon regeneration, then some therapeutic effect may be achieved, but delivery efficiency is low and side effects occur
Solution Approach 1:
The patent employs self-delivering siRNA (sdRNA) molecules that autonomously navigate to and enter target cells without requiring external delivery vehicles or complex transfection protocols. The sdRNA molecules self-assemble and self-translocate across cell membranes, eliminating the need for liposomes, viral vectors, or other carrier systems, thereby achieving high delivery efficiency while maintaining therapeutic efficacy and reducing side effects associated with traditional delivery methods
Solution Approach 2:
The patent introduces sdRNA as an intermediary molecule that bridges the gap between therapeutic intent and cellular action. These modified siRNA molecules serve as self-sufficient carriers that mediate the delivery of genetic silencing machinery directly into target cells, replacing complex delivery systems while maintaining reliable therapeutic effects through their inherent cell-permeable properties
2Reliability
If growth inhibitory proteins are present in the CNS environment, then they maintain normal CNS function, but they prevent axon regeneration and recovery
Solution Approach 1:
The patent converts the harmful presence of growth inhibitory proteins into a beneficial therapeutic opportunity by using sdRNA to specifically silence these proteins. The approach transforms the obstacle of inhibitory proteins into a target for selective silencing, allowing regeneration to proceed while normal CNS functions are preserved through targeted rather than broad suppression
Solution Approach 2:
The patent applies local quality by directing sdRNA treatment specifically to the injured spinal cord region where growth inhibitory proteins are most problematic. The sdRNA molecules are administered locally at the injury site, creating a localized silencing effect that addresses regeneration inhibition without broadly suppressing normal CNS functions in unaffected areas
3Reliability
If intrinsic signaling pathways are upregulated in mature neurons, then they regulate normal neuronal function, but they suppress axon regrowth after injury
Solution Approach 1:
The patent applies parameter changes by selectively altering the expression levels of specific intrinsic signaling proteins (such as PTEN) in injured neurons using sdRNA. This targeted silencing changes the signaling parameter balance, reducing the suppressive effect on axon regrowth while preserving other essential neuronal functions that depend on normal signaling pathway activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sdRNAs effectively silence PTEN expression, leading to enhanced axon regeneration, astrocyte migration, and oligodendrocyte proliferation, improving recovery in SCI by overcoming the barriers of the CNS environment and reducing side effects associated with traditional delivery methods.
Implementation Method 1
Treatment of CNS injury with RNAi therapeutics
Data Source
AI summary
Self-delivering PTEN RNA and methods of reducing PTEN expression are provided herein. Also provided are methods of treating spinal cord injury (SCI) and other neurotrauma with PTEN sdRNA.